The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Pfizer’s victory in London court invalidates two GSK patents for respiratory syncytial virus (RSV) vaccine. GSK plans to ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...

We receive compensation from the products and services mentioned in this story, but the opinions are the author's own. Compensation may impact where offers appear. We have not included all available ...

Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy ...

NHL fans displeased with Wayne Gretzky's new commercial for AREXVY vaccine. (Image Source: Imagn). NHL fans have expressed their dissatisfaction on social media regarding Wayne Gretzky's latest ...